Compare AAPL & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAPL | AZN |
|---|---|---|
| Founded | 1977 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5T | 250.7B |
| IPO Year | 1994 | 1995 |
| Metric | AAPL | AZN |
|---|---|---|
| Price | $347.59 | $172.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 44 | 12 |
| Target Price | ★ $329.38 | $207.16 |
| AVG Volume (30 Days) | ★ 26.3M | 2.4M |
| Earning Date | 11-02-2026 | 10-30-2026 |
| Dividend Yield | 0.31% | ★ 1.92% |
| EPS Growth | ★ 22.70 | N/A |
| EPS | ★ 6.88 | N/A |
| Revenue | ★ $265,595,000,000.00 | N/A |
| Revenue This Year | $14.91 | $7.94 |
| Revenue Next Year | $10.43 | $6.26 |
| P/E Ratio | $50.03 | ★ $31.91 |
| Revenue Growth | ★ 15.86 | N/A |
| 52 Week Low | $243.42 | $80.48 |
| 52 Week High | $348.15 | $212.71 |
| Indicator | AAPL | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 65.22 | 64.63 |
| Support Level | $325.81 | $154.70 |
| Resistance Level | N/A | $175.04 |
| Average True Range (ATR) | 5.85 | 3.15 |
| MACD | 0.06 | 1.41 |
| Stochastic Oscillator | 95.98 | 92.97 |
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.